International journal of nanomedicineApr 28, 2026

Nanoparticle Treatments for Osteoarthritis Targeting Aging, Metabolism, and Inflammation

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Abstract

Osteoarthritis is a multifactorial joint failure syndrome driven by cellular senescence, metabolic dysregulation, and low-grade chronic inflammation.

Cellular senescence, metabolic dysregulation, and chronic inflammation are interconnected factors that disrupt joint health in osteoarthritis.
Current therapies mainly provide symptomatic relief without addressing the underlying causes of the disease.
Nanomaterial-based platforms may enable targeted interventions by leveraging their customizable surface properties and ability to deliver therapies directly to affected areas.
Innovative approaches include using nanomaterials for clearing senescent cells, reprogramming metabolism, and repolarizing immune cells to promote joint health.
These advancements aim to not only slow the progression of osteoarthritis but also potentially restore healthy joint function.

Simplified

Osteoarthritis (OA) is no longer viewed as a mere "wear-and-tear" disease, but rather as a multifactorial joint failure syndrome driven by cellular senescence, metabolic dysregulation, and low-grade chronic inflammation. These pathological pillars synergistically disrupt cartilage homeostasis, subchondral bone remodeling, and synovial inflammation, collectively fueling disease progression. While conventional therapies offer only symptomatic relief, they fail to reverse or reprogram the underlying pathological microenvironment. Consequently, there is an urgent need to develop disease-modifying interventions that can simultaneously target these pathological pillars. Here, we critically examine how nanomaterial-based platforms-leveraging tailorable surface chemistry, cartilage-penetrating dimensions, and stimuli-responsive cargo release-enable precision targeting of these interconnected mechanisms. We highlight advances in senolytic delivery for senescent cell clearance, redox-modulating nanozymes for metabolic reprogramming, and immunoregulatory strategies for macrophage repolarization, emphasizing designs that transcend passive drug delivery to actively remodel the joint microenvironment. By integrating mechanistic insights with engineering innovation, this review outlines a roadmap for next-generation disease-modifying nanomedicines that promise not merely to slow OA progression, but to restore the biological clock of the joint. We also discuss current translational barriers and propose future directions for personalized OA therapy.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

No potential conflict of interest was reported by the author(s).

PubMed

Nanoparticle Treatments for Osteoarthritis Targeting Aging, Metabolism, and Inflammation

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief